Electrotherapy medical device maker Zynex has received US Food and Drug Administration (FDA) clearance for its NexWave device.

The NexWave device is capable of delivering three modalities of stimulation: transcutaneous electrical nerve stimulation, interferential electrical stimulation and neuromuscular electrical stimulation.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Zynex CEO Thomas Sandgaard said that the combined modalities of the company’s NexWave provide doctors and clinicians a comprehensive pain therapy solution for their patients.

”We believe this new product is unique in the electrotherapy industry and provides our sales force with a competitive edge to fuel revenue generation in our already rapidly growing Zynex Medical subsidiary," Sandgaard added.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact